Number of shares and voting rights of ADOCIA as of April 30, 2020
May 11 2020 - 12:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA, (Paris:ADOC) a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
diabetes treatment with innovative formulations of approved
proteins, releases its total number of outstanding shares as well
as its voting rights as of April 30, 2020.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting
rights (1)
Total number of exercisable
voting rights (2)
April
04/30/2020
6 962 294
9 738 665
9 715 738
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
other metabolic diseases. In the diabetes field, Adocia’s portfolio
of injectable treatments is among the largest and most
differentiated of the industry, featuring five clinical-stage
products. Adocia aims to expand its portfolio towards the treatment
of other metabolic diseases and their comorbidities.
The proprietary BioChaperone® technological platform is designed
to enhance the effectiveness and/or safety of therapeutic proteins
while making them easier for patients to use. Adocia customizes
BioChaperone to each protein for a given application. Adocia’s
clinical pipeline includes four novel insulin formulations for the
treatment of diabetes: two ultra-rapid formulations of insulin
analog lispro (BioChaperone® Lispro U100 and U200), a combination
of basal insulin glargine and rapid-acting insulin lispro
(BioChaperone® Combo) and a combination of a prandial insulin with
amylin analog pramlintide (M1 pram - ADO09). It also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia. Adocia preclinical pipeline includes
combinations of insulin glargine with GLP-1 receptor agonists
(BioChaperone® Glargine GLP-1) for the treatment of diabetes and a
ready-to-use combination of glucagon and a GLP-1 receptor agonist
(BioChaperone® Glucagon GLP1) for the treatment of obesity. Adocia
is also exploring in preclinic the potential of its M1 Pram
combination to treat people with type 2 diabetes suffering from
neurological comorbidities, including Alzheimer’s disease.
In 2018, Adocia and Chinese insulin leader Tonghua Dongbao
entered a strategic alliance. In April 2018, Adocia granted Tonghua
Dongbao licenses to develop and commercialize BioChaperone Lispro
and BioChaperone Combo in China and other Asian and Middle Eastern
territories. The licensing agreements included USD 50 million
upfront and up to USD 85 million development milestones, plus
double-digit royalties on sales. In June 2018, Tonghua Dongbao
agreed to manufacture and supply active pharmaceutical ingredients
insulin lispro and insulin glargine to Adocia globally, excluding
China, to support Adocia’s portfolio development and
commercialization.
Adocia aims to deliver “Innovative medicine for everyone,
everywhere.” To learn more about Adocia, please visit us at
www.adocia.com
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Reference Document filed
with the French Autorité des marchés financiers on April 22, 2020
(a copy of which is available at www.adocia.com) and to the
development of economic conditions, financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Adocia to be
materially different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200511005430/en/
Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph. : +33 4 72 610
610
Adocia Press Relations Europe MC Services AG
Raimund Gabriel adocia@mc-services.eu
Ph. : +49 89 210 2280
Adocia Investor Relations USA The Ruth Group Tram
Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024